Oncology is the largest therapeutic area in the pharmaceutical industry by sales, but right now, weight management is the hottest. This market is predicted to grow rapidly in the next decade, ...

A phase 2 study of Pfizer’s atirmociclib has hit its primary endpoint, providing evidence that the CDK4 inhibitor improves ...

Good morning. What happens to an organization after it achieves a moonshot? That has been Albert Bourla’s reality, post-COVID. As the CEO of Pfizer, a company he first joined in 1993, Bourla—a ...

Pfizer’s battle with Novo Nordisk over control of obesity drug developer Metsera is getting nasty. After Pfizer apparently sealed a $4.9 billion purchase of Metsera in September, Novo Nordisk swooped ...

Vaccine candidate PF-07307405 (LB6V) demonstrated more than 70% efficacy in preventing Lyme disease in individuals aged five years and above -- The investigational vaccine candidate was well tolerated ...

Metsera said Novo Nordisk's new bid for the obesity biotech is "superior" to a revised offer from Pfizer, escalating a heated tussle over the startup between the two pharmaceutical giants. Novo ...

While much of the biopharma industry has spent the past 12 months treading lightly around the Trump administration and the tumult it has wrought on U.S. medical research and regulation, Pfizer’s CEO ...

Pfizer CEO Albert Bourla joins Squawk on the Street to discuss the company’s up to $10 billion acquisition of Metsera, the competitive landscape in obesity drugs, and Pfizer’s strategy for clinical ...

Pfizer's CEO said Sunday that the company is "days" away from submitting data to the FDA in the hopes of having its COVID-19 vaccine approved for children as young as 5. In speaking ABC News on Sunday ...

(Reuters) -Pfizer on Thursday closed its up to $10 billion acquisition of Metsera after winning shareholder approval, gaining a foothold in the fast-growing obesity market following a fierce bidding ...

Pfizer's CEO thinks his company will make big waves in the weight loss market. Eli Lilly does have a strong hold on the industry and won't let go anytime soon. Even so, Lilly could carve out a niche ...